PAX5 and lung adenocarcinoma: In NSCLC, PAX5 was significantly down‐regulated in lung adenocarcinoma, but not in squamous‐cell lung carcinoma (P < 0.01, Fig. 1A), through analysing the online microarray database (www.oncomine.org, Compendia Bioscience, Ann Arbor, MI, USA).